Moderna and Merck Crack Cancer Vaccine Code After Century-Long Quest

Moderna and Merck have achieved a breakthrough in cancer vaccine development after decades of failures. The companies announced their success on August 13, with Moderna CEO Stephane Bancel receiving a call while celebrating a friend's birthday at a Lebanese restaurant.

The breakthrough is significant because it represents the first major success in cancer vaccine research in over a century. Despite numerous attempts by pharmaceutical companies and researchers, previous efforts have been met with failure.

Moderna and Merck's vaccine uses mRNA technology to stimulate the body's immune response against cancer cells. This approach has shown promise in treating various types of cancer, including melanoma and lung cancer.